Travere Therapeutics, Inc. (Travere) is an integrated biopharmaceutical company the is focused on identifying, developing and delivering therapies to people with rare diseases. Travereâ€™s products include Chenodal (chenodiol tablets), holbam (cholic acid capsules) and Thiola and Thiola EC (tiopronin tablets). Chenodal, which is for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Cholbam, which is for the treatment of bile acid synthesis disorders due to single enzyme defects. Thiola and Thiola EC, which are for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. The Company's clinical program Sparsentan (RE-021), is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (ERA), with in vitro selectivity toward endothelin receptor type A, and a potent angiotensin receptor blocker (ARB).
Number of employees : 262 people.
|Tiopronin Products||95.64||54.5%||108.88||54.9%|| +13.85%|
|Bile Acid Products||79.70||45.5%||89.44||45.1%|| +12.22%|
|USD in Million
|United States||175.34||100%||198.32||100%|| +13.11%|
|USD in Million
|Vote ||Quantity||Free-Float||Company-owned shares||Total Float
|RA Capital Management LP ||5,614,428||
|Armistice Capital LLC ||4,748,000||
|Janus Capital Management LLC ||4,023,074||
|Macquarie Investment Management Business Trust ||3,950,209||
|The Vanguard Group, Inc. ||3,768,529||
|Deep Track Capital LP ||3,090,200||
|SSgA Funds Management, Inc. ||2,782,323||
|Consonance Capital Management LP ||2,314,421||
|Baker Bros. Advisors LP ||2,039,772||
|Perceptive Advisors LLC ||1,965,555||
Sector Bio Therapeutic Drugs
Connections : Travere Therapeutics, Inc.